secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-060716
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya reports Q3 net loss $3.4M, cash $10.9M; Phase 2 AD topline due summer 2024
-------------------------------------------------------------------------------

- Net loss $3.4M ($0.34/share) vs $4.0M ($1.55/share) in Q3 2022; cash $10.9M up from $5.9M at Dec 2022.
- R&D expenses $1.6M, G&A $2.0M; net loss per share improved due to increase in shares outstanding to 9.95M.
- Completed enrollment (38 patients) in Phase 2 double-blind placebo-controlled trial of LD IL-2 in Alzheimer's; topline data expected summer 2024.
- Plan to submit IND for Phase 2 trial of COYA 302 in ALS in 1H 2024; also licensed exosome engineering technology from Carnegie Mellon.
- Appointed Dieter Weinand to board, Dr. Fred Grossman as President & CMO, and Dr. Merit Cudkowicz as clinical advisor in recent months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000095017023060716/0000950170-23-060716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000095017023060716/coya-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer